Another example of targeting tumor-associated antigens is the use of in vitro-activated T cells armed with GD2Bi-aATC, a bispecific antibody that recognizes CD3 and GD2 (231, 232), in combination with IL-2 and GM-CSF in patients with neuroblastoma or osteosarcoma (NCT02173093). The gene discussed is IL2; the disease is neoplasm.